



# ENGOT ov26 / PRIMA Study



Platinum responsive ovarian cancer  
Stage III or IV ovarian  
CR or PR with front line platinum-based chemotherapy  
HRDpos or HRDneg/not determined (nd) tumor

pre-enrollment screening:  
•centralized HRD testing for all patients  
•local sBRCA and/or gBRCA test results are allowed



Stratification factors:  
•Use of NACT: yes or no  
•Best tumor response: CR or PR  
•HRD status: pos or neg/nd

• Patients with sBRAC or tBRCAmut will be stratified as HRDpos  
• Patients with unknown or wild type BRCA will be stratified based on HRD test results


Primary Endpoint	<b>PFS in HRDpos patients; hierarchical analysis for all patients regardless of HRD status</b>
Key Secondary Endpoints	<b>Overall survival (OS), patient reported outcomes (PRO's), time to first subsequent treatment, progression- survival-2 , time to CA-125 progression, safety and tolerability of study therapy</b>

HRD=homologous recombination deficiency; CR=complete response; PR=partial response; PFS=progression-free survival;



Ongoing Trials – status update

Trial name/Group name and number



Trial setting: Maintenance 1<sup>st</sup> line with Niraparib

Study Design: ENGOT MODEL C

Sponsor(s): TESARO

Lead Group: GEICO (PI: A. González-Martín)

Planned No. of patients: 330

Current accrual: 246

Expected to end recruitment by Q2 2018